Complement C1 inhibitor protein - Shire plc

Drug Profile

Complement C1 inhibitor protein - Shire plc

Alternative Names: C1 Esterase Inhibitor (human); C1 INH-nf; C1-INH; Cetor; Cinryze; SHP-616; SHP616 Liquid

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanquin Blood Supply Foundation
  • Developer Sanquin Blood Supply Foundation; Shire; Shire ViroPharma; ViroPharma
  • Class Complement C1 inactivator proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase III Transplant rejection
  • No development reported Autoimmune haemolytic anaemia; Delayed graft function; Myocardial infarction; Neuromyelitis optica
  • Discontinued Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Autoimmune-haemolytic-anaemia in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Neuromyelitis-optica(Adjunctive treatment) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Delayed-graft-function in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top